AGI-24512

CAS No. 2201066-53-5

AGI-24512( —— )

Catalog No. M23992 CAS No. 2201066-53-5

AGI-24512 is a inhibitor of methionine adenosyltransferase 2A (MATA2 ).It is useful for treatment of cancer and blocks growth of MTAP-deleted cancer cells in vitro.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 410 In Stock
50MG 1782 In Stock
100MG 2250 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    AGI-24512
  • Note
    Research use only, not for human use.
  • Brief Description
    AGI-24512 is a inhibitor of methionine adenosyltransferase 2A (MATA2 ).It is useful for treatment of cancer and blocks growth of MTAP-deleted cancer cells in vitro.
  • Description
    AGI-24512 is a inhibitor of methionine adenosyltransferase 2A (MATA2 ).It is useful for treatment of cancer and blocks growth of MTAP-deleted cancer cells in vitro.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    MATA2
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2201066-53-5
  • Formula Weight
    400.47
  • Molecular Formula
    C24H24N4O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:125 mg/mL (312.13 mM; Need ultrasonic);H2O:< 0.1 mg/mL (insoluble)
  • SMILES
    CC1=C(C(=O)N2C(=N1)C(=C(N2)C3=CC=CC=C3)N4CCCCC4)C5=CC=C(C=C5)O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Agios. Targeting MAT2A in MTAP-deleted Cancers. Presented at the American Association for Cancer Research (AACR) Annual Meeting, April 14-18, 2018, Chicago, IL, USA
molnova catalog
related products
  • MRK-740

    MRK-740 is a potent and selective inhibitor of PRDM9 histone methyltransferase.MRK-740 inhibits other histone methyltransferases and inhibits PRDM9-dependent H3K4 trimethylation.

  • beta-Amyrin palmitat...

    Beta-Amyrin palmitate may release norepinephrine from newly synthesized pools, and thus, it may activate noradrenergic activity.

  • RGDV

    RGDV is a platelet aggregation inhibitor. RGDV inhibits platelet-dependent thrombus formation. RGDV is used for tumor recognition via the targeting effect.